Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite

The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply.

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth's specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing network.

Thomas Eisele, Chief Operations Officer, stated, "We are thrilled to officially open the new expansion to our bioconjugation facility in Berlin, which represents a significant enhancement to our existing operations. This suite enables the scalable, diverse, high-quality conjugation services that our customers need to advance to the next generation of therapies.”

Frank Leenders, General Manager for the Berlin site, commented, "The construction of our new facility, including class D and C cleanrooms, represents a natural evolution of our Berlin operation—in many ways we are growing alongside our customers. The additional refurbishment of our existing facility enhances our GMP manufacturing capabilities, reinforcing our commitment to meeting the evolving needs of our customers."

"Conjugation chemistry, advanced polymers and bioconjugation production are critical areas for many of our life science customers,” added Marie Leblanc, Executive Vice President, Life Sciences. “Being able to support projects fully, from initial bioconjugate process development to commercial GMP supply, enables us to provide specialized conjugation solutions for diagnostics and therapeutics—strengthening our position as a trusted partner in the Life Science industry.”

About Biosynth

Biosynth is a leading supplier of critical raw materials and services for the life sciences industry. With a deep commitment to quality, Biosynth serves pharmaceutical, diagnostics and life sciences research customers through its global network of R&D and production sites. Headquartered in Switzerland, Biosynth partners with customers worldwide to accelerate innovation and ensure reliability at every stage of development and manufacturing. For more information, please visit www.biosynth.com.